INTERNATIONAL 8th USBİLİM HEALTH, ENGINEERING AND APPLIED SCIENCES CONGRESS
INVESTIGATION OF POTENTIAL FOXM1 INHIBITORY ACTIVITIES OF TYPE 2 DIABETIC DRUGS
Yayıncı:
Akademik Paylaşım Platformu Publishing House - APP Publications
FOXM1 is a member of the Forkhead Box (FOX) transcription factor family. FOXM1 controls gene expression throughout the embryonic development processes and maintain cell homeostasis via regulating vital biologic processes for cells, such as cell proliferation, differentiation and apoptosis. Due to its role in cell homeostasis, FOXM1 became a common therapeutic target various diseases treatments, especially for cancer research. Troglitazone, a type 2 diabetes drug, is one of the known inhibitors of FOXM1. In our study, we aimed to investigate the potential inhibitory effect of other type 2 diabetic drugs on FOXM1 through molecular docking studies, protein-ligand interaction, and RMSD analyses, taking Troglitazone as our reference drug. Docking studies were performed using AutoDock Vina v1.5.7. Protein-ligand interactions between FOXM1 and the compounds were analyzed via PyMol v3.0.3 and Discover Studio 2024 Client. AutoDock Tools v1.5.7 was used to perform RMSD analyses. In conclusion, Glimepiride and Linagliptin stood out as a promising candidate as FOXM1 inhibitors. Meanwhile, the fact that Metformin can inhibit FOXM1 in in vivo studies, even though for our study Metformin’s affinity was lower than desired, underlined that the working mechanism of Glimepiride and Linagliptin should be examined through FOXM1 inhibition in future in vivo and clinical studies.
